BioSpace News Archive

Pulse Biosciences, Inc. today announced a collaboration with CardioNXT, to support Pulse Biosciences’ planned nsPFA cardiac catheter first-in-human study focused on the treatment of atrial fibrillation.

Mirum Pharmaceuticals, Inc. today announced positive data from the Phase 3 RESTORE study evaluating Chenodal® (chenodiol) tablets in 13 adult patients with cerebrotendinous xanthomatosis, or CTX.

Sengenics Corporation LLC today announced the launch of i-Ome Discovery, a comprehensive protein microarray platform for the analysis of autoantibodies associated with disease diagnosis and therapeutic intervention.

RenovoRx, Inc today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the acceptance of several abstracts for presentation at the hybrid 2023 Northeast ALS Consortium (NEALS) Annual Meeting.

Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, announced the completion of their previously announced acquisition of Baxter International Inc.’s BioPharma Solutions business.

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today that on September 26, 2023, the USPTO granted a patent for its lead clinical asset, NEO-201, which is currently being tested in Phase 2 human Clinical Trials in the US.

In a transformative move bolstering its position in the realm of neurodegenerative therapies and Alzheimer’s disease research, ADvantage Therapeutics, Inc. announced the appointment of Carmela R. Abraham, Ph.D. as its Chief Science Officer.

Baylor Genetics announced its scientists and genetic counselors will present 10 research abstracts at three major upcoming conferences, including the National Organization for Rare Disorders Breakthrough Summit, National Society of Genetic Counselors Annual Conference, and the American Society of Human Genetics Annual Meeting.

Novarum DX Ltd, the mobile software arm of BBI Solutions, has announced it has been bought out by a small group of specialist investors and the existing management. The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets.